Maxim analyst Jason McCarthy downgraded Cero Therapeutics (CERO) to Hold from Buy.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CERO:
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
- Why Is CERo Therapeutics Stock Down 80% Today?
- CERo Therapeutics Faces Nasdaq Delisting Suspension
- Cero Therapeutics discloses Nasdaq Panel listing determination
- Cero Therapeutics’ Innovative AML Treatment Study: A Potential Game-Changer?